A5021 297

AAV-2 rep homologue 51-2 acute and chronic infections 330-2

serologic testing 91-100 acute lymphoblastic leukaemia 195 acute primary infection 65, 143 acyclovir 258, 286-7, 293, 296 adenovirus 238, 248 AIDS 271, 272-4 HHV-6, opportunistic agent 269, 270 related LD 194-5 alpha interferon 338 alphaherpesvirus 12, 13 amplicons 28 ampligen 259

angioimmunoblastic lymphadenopathy disease

(AILD) 193-4 animal models 305-16 anti-herpesvirus therapy, new targets 297-9 anti-inflammatory (Th2) cytokine 203-4 antibodies 54, 61, 91, 307

characterization 95-6 antibody titer 91, 94, 97-8, 120, 229-30, 245, 337 anticomplement immunofluorescence assay (ACIF) 93

anticonvulsant hypersensitivity syndrome systemic manifestation, dilantin 150 antigenemia assay 84, 166 antigens 94, 94-5, 136f, 140f, 142, 219, 259, 292,

312-13, 313-15 antiviral assays 291-2 antiviral therapy 287, 296

CFS 258-9, 260 apoptosis 140f, 316 assembly 11

and maturation 13-15 astrogliosis 215

atypical lymphoproliferations (APLs) 187-90

B-cell lymphomas 159, 193 B-cells 7, 159 BDCRB 298-9

betaherpesviruses 11, 12, 38, 280-81, 307 gene encode 39

localized cpg suppression 28-9 Roseolavirus 47, 133 U51 51

biological aspects, of HHV-6 variants 82-3, 134

T-lymphotropic virus 82 biological features 59-71 cellular receptor 60-1 cellular tropism 62-5 effects on host cell 65-71 species specificity 61-2 blastic transformation 135, 139, 140f blood vessels diseases 234-6 bone marrow progenitor cells (CD34+) 65 bone marrow suppression 282 bone marrow transplant (BMT) 205-6 brain 215, 217

axial SPECT image 257f Burkitt's lymphoma 187

Callithrix jacchus jacchus 305, 309, 310 Canale-Smith syndrome 188, 198 capsid structure 12, 15 comparisons 18-19 three-dimensional structure 16-18 cardiac arteriole endothelial cells 235f cardiovascular pathology 233-9 blood vessels diseases 234-6 heart diseases 236-9 cardiovascular system 142, 225-32 CD4 lymphocytes 254, 308, 324, 325-7, 333 CD4+ T cells, productive coinfection by HHV6 and HIV-1 264f, 265-6 CD8 70, 324 CD34+ 65, 186

307-8 CD122 expression 159 cell and tissue tropism strain differences 134-5 cell-free body fluids, PCR analysis 107

cell lines 16, 64, 106, 267 cell proliferations by cytokine network dysregulation 198 cellular homologues 37-8, 50-1 cellular host range in vivo 65 cellular immune response 216 mathematical model 323-4, 325-7 parameter optimization 327-30 simulation results 330-2 cellular immune system 201-10 current immunological tools 206-9 isolation history, immunodeficiency disorders 202

subversion 202-4

transplantation, reactivation 204-6 cellular pathology 135 cellular reactions 136f, 138f cellular receptor 15, 222, 271, 273

CD46 60-1, 218 cellular transformation 67 cellular tropism 24-6, 62-5, 70, 265

HHV-6 and HHV-7 25, 37 central nervous system (CNS) 84-5, 142, 255, 256-8, 295

CNS demyelination 312-6 febrile seizures 214-5 HHV-6 infection 213-4, 215, 257f mesial temporal-lobe epilepsy (MTLE) 215 multiple sclerosis (MS) 215-8 progressive multifocal leukoencephalopathy (PML) 219-20 cerebral lymphomas 194 characteristic tissue reaction 140f chronic allograft nephropathy 205, 286 chronic fatigue syndrome (CFS) 86-7, 207-9, 251-2, 309

clinical algorithm 257f CNS, HHV-6 in 256-8 HHV-6 association with 254-6 HHV-6 diagnostic testing 259-60 HHV-6 therapy 258-9 identifying subsets 254 immune dysfunction 252-3 immunomodulatory therapy 259 proposed pathogenic model 253-4 viral implication 253 chronic hepatitis 244 cidofovir 258, 293

lipophilic ester prodrugs 297 CNS disease 84-5, 98-9 complement activation, dysregulation of 71 computational simulation model development 325-7 parameter optimization 327-30 simulation results 330-3 corticosteroid 155, 160 CryoEM imaging 16, 17f, 18f cyclopropavir 297 cytokines 246, 285, 338

cytomegalovirus (CMV) 9, 141, 204-5, 225, 282, 285, 295

cytopathic effects (CPE) 25, 65-6, 93

de novo CD4 expression

HHV-6 B-infected Jurkat cells 267-8 dialyzable leukocyte extract see transfer factor diarrhea 247-8

intussusception 248 direct repeat (DR), genome 9, 26, 27f DNA core 12, 14f DR7 protein 195-6 DRESS 150-1, 152-4 clinical spectrum 151-2 HHV-6 reactivation 154-9 therapeutic implications 159-60 visceral symptoms 151f, 155 drug exposure 151f, 158, 160, 167, 246 drug-induced hypersensitivity syndrome (DHS) 151-2, 167, 171, 250 cutaneous lesion 150 drug exposure 150, 167, 246 hepatic injury, HHV-6 infection in 167-8, 245, 246

drug reaction with eosinophilia and systemic symptoms see DRESS

Was this article helpful?

0 0
How To Bolster Your Immune System

How To Bolster Your Immune System

All Natural Immune Boosters Proven To Fight Infection, Disease And More. Discover A Natural, Safe Effective Way To Boost Your Immune System Using Ingredients From Your Kitchen Cupboard. The only common sense, no holds barred guide to hit the market today no gimmicks, no pills, just old fashioned common sense remedies to cure colds, influenza, viral infections and more.

Get My Free Audio Book


Post a comment